Title:Tirzepatide: A First-in-class Twincretin for the Management of Type 2
Diabetes
Volume: 21
Issue: 6
Author(s): Shalini Jaswal, Priya Bisht, Rajiv Patel, Darakhshan Parveen, Ghanshyam Das Gupta and Sant Kumar Verma*
Affiliation:
- Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga-142 001, Punjab, India
Keywords:
Tirzepatide, type 2 diabetes, glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), atherosclerosis, amino acids.
Abstract:
Background: Tirzepatide (LY3298176) was approved by U.S. Food and Drug Administration
(FDA) on May 13th, 2022. The drug was developed by Eli Lilly and Co. and marketed under the trade
name of ‘Mounjaro’, a first-in-class ‘Twincretin’, which is a dual activator of GIP and GLP-1 receptors,
resulting in improved blood sugar control in type 2 diabetics The review covered the comprehensive insight
on the drug discovery journey of tirzepatide.
Methods: Using the keywords "Tirzepatide", "Twincretin", "Type 2 Diabetes", "GLP-1", and "GIP," data
were gathered from Medline, PubMed, Google Scholar, and Science Direct.
Results: The review covers comprehensive insight into the drug discovery journey of tirzepatide. The
drug-target structural specialty has been discussed to establish the dual inhibition mechanism of action of
tirzepatide. The results of in vitro studies, preclinical and clinical trial data, pharmacokinetic profile, dosing
regimen, side effects, and toxicities of tirzepatide are reviewed to account for the potency, efficacy,
and safety of the newly approved drug. The drug molecule may attain a privileged status in the antidiabetic
market as the clinical data showed that it effectively reduces HbA1c level in monotherapy as well
as in add-on therapy, compared to placebo, semaglutide, insulin degludec, and insulin glargine, and found
effective in type 2 diabetes associated conditions like atherogenic dyslipidemia and non-alcoholic steatohepatitis.
Conclusion: Tirzepatide is a clinically efficient drug, exhibiting a good safety profile as evident from the
existing clinical data, and could be a new alternative to the currently available antidiabetics for the treatment
of T2D.